Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul;3(3):182-4.
doi: 10.4103/2278-330X.136811.

Tolvaptan

Bharath Rangarajan  1 , Vineetha Binoy  1 , Sachin Sharatchandra Hingmire  2 , Vanita Noronha  3
Affiliations

Tolvaptan

Bharath Rangarajan et al. South Asian J Cancer. 2014 Jul.

Abstract

Hyponatremia is a common and often under-recogonised clinical problem in oncologic practice. The recogonition of the cause of hyponatremia and initiation of appropriate and timely intervention can prevent morbidity and improve treatment tolerance. This drug review aims at discussing the currently approved oral vaptanagent Tolvaptan. Vaptans including Tolvaptan act as "aquaretic" agents cousing excretion of water while retaining the sodium. Administration of this agent for prescribed periods result in improvement of serum sodium levels. The drug can be used in many clinical situations resulting in hyponatremia including congestive heart failure, cirrhosis and syndrome of inappropriate ADH secretion (SIADH) including SIADH related to malignancies.

Keywords: Hyponatremia; paraneoplastic syndrome; syndrome of inappropriate anti-diuretic hormone; tolvaptan.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Hoorn EJ, van der Lubbe N, Zietse R. SIADH and hyponatraemia: Why does it matter? NDT Plus. 2009;2(Suppl 3):iii5–11. - PMC - PubMed
    1. Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med. 2006;119:71.e1–8. - PubMed
    1. Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: The vaptans. Lancet. 2008;371:1624–32. - PubMed
    1. Hoorn EJ, Zietse R. Vasopressin-receptor antagonists. Future Cardiol. 2010;6:523–34. - PubMed
    1. Aditya S, Rattan A. Vaptans: A new option in the management of hyponatremia. Int J Appl Basic Med Res. 2012;2:77–83. - PMC - PubMed